Company Encyclopedia
View More
name
NeuroSense Therapeutics - Unit
NRSN.US
NeuroSense Therapeutics Ltd., a clinical-stage biotechnology company, focuses on discovering and developing treatments for patients suffering from debilitating neurodegenerative diseases in the United States and internationally. The company’s lead product is PrimeC, an extended-release oral formulation of a fixed-dose combination of ciprofloxacin and celecoxib, currently under Phase 2b/3 clinical trials for the treatment of amyotrophic lateral sclerosis, and completed Phase 2 clinical trials for the treatment of Alzheimer’s, as well as under preclinical studies for the treatment of Parkinson’s disease. Its preclinical pipeline includes StabiliC for the treatment of Parkinson's disease; and CogniC for the treatment of Alzheimer’s disease. The company was incorporated in 2017 and is headquartered in Herzliya, Israel.
1.932 T
NRSN.USMarket value -Rank by Market Cap -/-

Valuation analysis

portai
P/E
1Y
3Y
5Y
10Y
P/E
-
Industry Ranking
-/-
  • P/E
  • Price
  • High
  • Median
  • Low
P/B
1Y
3Y
5Y
10Y
P/B
-
Industry Ranking
-/-
  • P/B
  • Price
  • High
  • Median
  • Low
P/S
1Y
3Y
5Y
10Y
P/S
-
Industry Ranking
-/-
  • P/S
  • Price
  • High
  • Median
  • Low
Dividend Yield
1Y
3Y
5Y
10Y
Dividend Yield
-
Industry Ranking
-/-
  • Dividend Yield
  • Price
  • High
  • Median
  • Low

Institutional View & Shareholder

Analyst Ratings

Rating
Percentage
    • Price
      --
    • Highest
      --
    • Lowest
      --
    News
    View More

    NeuroSense reports positive safety results of PrimeC in Alzheimer's Phase 2 study. Q1 2026 to reveal clinical outcomes.

    NeuroSense Therapeutics Ltd., a biotechnology company based in Cambridge, Massachusetts, is set to reveal clinical and biomarker outcomes in the first quarter of 2026. The company, listed on NASDAQ as NRSN, specializes in developing groundbreaking treatments for severe neurodegenerative conditions. Keep an eye out for the latest developments from NeuroSense as they continue to advance in their late-clinical stage trials.

    Unusual Whales·
    US
    NRSN
    -0.12%
    Unusual Whales·
    US
    NRSN
    -0.12%

    NeuroSense Confirms Favorable Safety and Tolerability of PrimeC in an Alzheimer's Phase 2 Study | NRSN Stock News

    NeuroSense Therapeutics announced favorable safety and tolerability results for PrimeC in a Phase 2 Alzheimer's study. No serious adverse events were reported, and clinical outcomes will be analyzed with biomarker data, expected in Q1 2026. PrimeC targets multiple mechanisms of Alzheimer's and ALS, aiming to slow disease progression. NeuroSense focuses on developing treatments for neurodegenerative diseases, addressing significant unmet medical needs. Forward-looking statements highlight risks and uncertainties in clinical trials and regulatory processes.

    StockTitan·
    US
    NRSN
    -0.12%
    StockTitan·
    US
    NRSN
    -0.12%

    Amyotrophic Lateral Sclerosis market to grow due to rising disease prevalence, with promising therapies like Masitinib & PrimeC.

    The market for amyotrophic lateral sclerosis is projected to expand due to the rising prevalence of the disease. This growth is bolstered by the development of new pipeline therapies, including Masitinib from AB Sciences, PrimeC from Neurosense Therapeutics, RNS60 from Revalesio, IFB-088 from InFlectis BioScience, and NP001. These advancements are anticipated to drive growth in the market for ALS treatment in the upcoming years.

    Unusual Whales·
    US
    NRSN
    -0.12%
    Unusual Whales·
    US
    NRSN
    -0.12%

    Noble Financial Remains a Buy on Neurosense Therapeutics Ltd. (NRSN)

    Noble Financial's Robert LeBoyer reiterated a Buy rating for Neurosense Therapeutics Ltd., setting a price target of $9.00. Alliance Global Partners also maintained a Buy rating with a $7.50 target. LeBoyer, focusing on healthcare stocks, has an average return of -12.0% and a 26.98% success rate. TipRanks offers a Cyber Monday sale for its Premium insights and tools.

    Tip Ranks·
    US
    NRSN
    -0.12%
    Tip Ranks·
    US
    NRSN
    -0.12%

    NeuroSense Therapeutics Locks Database for Phase 2 Alzheimer's Trial with Topline Results Expected in 2026

    NeuroSense Therapeutics has completed data collection for its Phase 2 clinical trial of PrimeC in Alzheimer's disease, known as the RoAD study. The database is locked, and all clinical data from eight patients are finalized for analysis. Topline results are expected in Q1 2026, with further details to be discussed in a webinar on December 8. This update is informational and not financial advice.

    Reuters·
    US
    NRSN
    -0.12%
    Reuters·
    US
    NRSN
    -0.12%
    © 2025 Longbridge｜Disclaimer